Last Updated : March 17, 2025
Details
FilesGeneric Name:
elexacaftor/tezacaftor/ivacaftor and ivacaftor
Project Status:
Complete
Therapeutic Area:
Cystic fibrosis, F508del or responsive CFTR mutation, 2 years and older
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Call for patient/clinician input open:
Brand Name:
Trikafta
Project Line:
Reimbursement Review
Project Number:
SR0837-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Confirmed diagnosis of CF (with or without a F508del mutation) Age 2 years of age or older
Submission Type:
Initial
Fee Schedule:
Schedule E
Indications:
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro and/or clinical data.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | January 22, 2024 |
|---|---|
| Call for patient/clinician input closed | March 19, 2024 |
| Clarification: - Patient input submission received from Cystic Fibrosis Canada | |
| Submission received | March 05, 2024 |
| Submission accepted | March 20, 2024 |
| Review initiated | March 21, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | June 06, 2024 |
| Deadline for sponsors comments | June 17, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | August 16, 2024 |
| Expert committee meeting (initial) | August 28, 2024 |
| Draft recommendation issued to sponsor | September 10, 2024 |
| Draft recommendation posted for stakeholder feedback | September 19, 2024 |
| End of feedback period | October 04, 2024 |
| Final recommendation issued to sponsor and drug plans | October 17, 2024 |
| Final recommendation posted | November 04, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | October 31, 2024 |
| CADTH review report(s) posted | March 17, 2025 |
Files
Last Updated : March 17, 2025